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AT1 receptor antagonist combats oxidative stress and restores
nitric oxide signaling in the SHR
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AT1 receptor antagonist combats oxidative stress and restores Hypertension is accompanied by oxidative stress of
nitric oxide signaling in the SHR. The tubuloglomerular feed- large conduit blood vessels and certain organs, including
back (TGF) responses of the spontaneously hypertensive rat the kidney [1]. Presently, neither the cause of the oxida-(SHR) are under exaggerated regulation by angiotensin II
tive stress nor its role in the regulation of the tone of(Ang II) type 1 receptors (AT1-R). Since AT1-Rs enhance oxy-
gen radical (O22 ) generation, we tested the hypothesis that the the major renal resistance vessels is clear. Studies with a
exaggerated TGF was due to a diminished blunting by macula cell membrane-permeable form of superoxide dismutase
densa (MD)-derived nitric oxide (NO) because of excessive (SOD) or with the nitroxide SOD mimetic tempol haveAT1-R–dependent generation of O22 . Groups of SHR and con-
implicated oxygen radicals (O22 ) in the hypertensiontrol Wistar-Kyoto (WKY) rats received vehicle (Veh), the
[2, 3], renal vasoconstriction [4], and enhanced tubulo-AT1-R antagonist candesartan (Cand; 3 mg · kg21 · day21), or
nonspecific therapy with hydralazine 1 hydrochlorothiazide 1 glomerular feedback (TGF)-dependent tone of the renal
reserpine (HHR) for two weeks. Compared with WKY rats, afferent arteriole [5] of the spontaneously hypertensive
the elevated mean arterial pressure of SHR (WKY 125 6 2 vs.
rat (SHR) model.SHR 163 to 779 mm Hg, P , 0.001) was reduced (P , 0.001)
Angiotensin II (Ang II) induces oxidative stress, assimilarly in SHR by Cand and HHR (121 6 5 and 116 6
5 mm Hg, P 5 NS). The SHR had an increased maximal indicated by enhanced levels of 8-iso prostaglandin F2a
TGF response (change in stop flow pressure during luminal (8-iso-PGF2a) [6]. There is experimental evidence of ex-perfusion of fluid: SHR 11.2 6 0.5 vs. WKY 8.3 6 0.4 mm Hg,
cessive Ang II type 1 receptor (AT1-R)-dependent vaso-P , 0.01) and a reduced TGF response to blockade of neuro-
constriction specifically in the kidney of the SHRs. Thus,neal NO synthase (nNOS) in the MD with luminal 7-nitro-
indazole (7-NI: DTGF in WKY 2.8 6 0.4 vs. SHR 1.1 6 0.6 although the circulating levels of Ang II and intrarenal
mm Hg, P , 0.05). Although the elevated TGF responses of levels of Ang I, Ang II, and Ang 1–7 are normal or low in
SHR were normalized by both HHR and Cand, only Cand the SHR [7], there is an exaggerated blood pressure (BP)restored a normal TGF response to luminal perfusion of the
response to renin-angiotensin-aldosterone system (RAAS)MD with 7-NI (DTGF with 7-NI in SHR: Veh 1 1.8 6 0.4 vs.
Cand 1 3.4 6 0.5 mm Hg, P , 0.05). To abrogate the local blockade [8] and an exaggerated renal vasoconstrictor
effects of O22 , tempol (a membrane-permeable superoxide dis- response to Ang II [9, 10] that cannot be ascribed to
mutase mimetic) was perfused into the efferent arteriole. Dur- enhanced renal or glomerular expression of AT1 or AT2ing tempol, SHR given vehicle or HHR had a much increased
receptors [9, 11, 12]. The enhanced response to Ang II isresponse to blockade of nNOS with 7-NI (DTGF in SHR with
specific for the kidney [10] and may underlie an enhanced7-NI during tempol: Veh 6.3 6 1.0 and HHR 4.5 6 0.8 mm Hg,
P , 0.01 vs. no tempol for both), implying that the effects of hypertensinogenic action of Ang II in the SHR [13].
NO had been prevented because of excessive O22 . In contrast, Nitric oxide (NO) generated from a neuroneal or type 1
the TGF response to 7-NI in SHR given Cand was unaffected
constitutive nitric oxide synthase (nNOS) that is heavilyby tempol (DTGF with 7-NI during tempol: 2.9 6 0.9, P 5 NS,
expressed in macula densa (MD) cells is activated duringcompared with no tempol). In conclusion, TGF responses of
SHR are exaggerated because of the effects of hypertension MD solute reabsorption. It normally blunts the expres-
and AT1-R. AT1-R blockade specifically diminishes oxidative sion of the TGF response [14]. We found evidence that
stress and restores NO signaling in the juxtaglomerular appara-
production of O22 in the juxtaglomerular apparatus (JGA)tus of the SHR.
opposes the normal buffering of TGF by MD-derived
NO [15]. This effect of O22 is exaggerated in the JGAKey words: oxygen radicals, reactive oxygen species, tubuloglomerular
of the SHR [5]. The functional effects of O22 could befeedback, hypertension, glomerular filtration rate, tempol, 7-nitroind-
azole, candesartan. corrected by microperfusion of tempol, which is a mem-
brane-permeable nitroxide SOD mimetic [16, 17] intoReceived for publication December 23, 1999
the efferent arteriole (EA) that supplies the peritubularand in revised form September 6, 2000
Accepted for publication October 10, 2000 capillaries and the interstitium around the MD region.
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receptors [18–20]. Recent studies have shown that short- euvolemic state [24]. Micropuncture studies were begun
after 60 minutes for stabilization.term AT1-R blockade can restore a normal TGF response
Clearance studies were undertaken during the micro-in the SHR [21]. Therefore, the present studies were
puncture measurements. [3H]-inulin (0.1 mCi · mL21; ICNdesigned to test the hypothesis that AT1-R–dependent
Biochemicals, Costa Mesa, CA, USA) was added to theoxidative stress in the JGA of the SHR model eclipses
intravenous fluid infusion. Urine was obtained from thethe blunting of the TGF response by MD-derived NO.
bladder, and blood was sampled at the midpoint. The mi-These experiments utilized groups of SHR and control
cropuncture period lasted 60 to 90 minutes, during whichWistar-Kyoto (WKY) normotensive rats treated for two
a renal clearance was undertaken with a blood sampleweeks with a vehicle or with a long-acting AT1-R antago-
drawn at the midpoint. Values of MAP and heart ratenist, candesartan. Additional groups received equi-anti-
(HR) were obtained over 15-minute intervals during thishypertensive therapy with hydralazine, hydrochlorothia-
period and were averaged.zide, and reserpine (HHR) that was designed to lower
For orthograde microperfusion of the loop of HenleBP similarly to candesartan but leave intact the AT1-R
(LH), a micropipette (8 mm OD) containing artificialand stimulate the RAAS [22]. The effects of MD-derived
tubular fluid (ATF) stained with FD&C dye was insertedNO were deduced from the responses to luminal micro-
into a late proximal tubule [24]. Injections of the coloredperfusions of the relatively nNOS-specific antagonist
ATF identified the nephron and the direction of flow.7-nitroindazole (7-NI) [23]. The effects of oxidative
An immobile bone wax block was inserted into this mi-stress mediated by O22 in preventing the blunting of TGF
cropuncture site via a micropipette (10 to 15 mm) con-by MD-derived NO were deduced from the effects of
nected to a hydraulic drive (Trent Wells, Inc., La Jolla,microperfusion of tempol into the EA supplying the test
CA, USA) to halt tubular fluid flow. A perfusion micro-nephron on the TGF response to luminal microperfusion
pipette (6 to 8 mm) containing ATF with test compoundsof 7-NI. These experiments obviate the confounding ef-
or vehicle was inserted into the proximal tubule down-fects produced by systemic administration of these antag-
stream from the wax block and connected to a nanoliteronists and directly target the JGA.
perfusion pump (WPI, Sarasota, FL, USA). A pressure
micropipette (1 to 2 mm) was inserted into the proximal
tubule upstream from the wax block to measure proximalMETHODS
stop flow pressure (PSF). The pressure was recorded byStudies were undertaken on male SHRs and WKY
a servo-null instrument (Instruments for Physiology andrats whose initial weights were 200 to 250 g (obtained
Medicine, La Jolla, CA, USA). Changes in PSF are anfrom Harlan-Sprague-Dawley, Madison, WI, USA). They
index of changes in glomerular capillary hydraulic pres-were maintained on a standard rat chow (Purina, St. Louis,
sure. Measurements of PSF were made in each nephronMO, USA) with a sodium content of 0.3 g21 · 100 g21 for
during zero loop perfusion and during perfusion withone to two weeks before study. They were allowed free
ATF at 40 nL · min21. This produces a maximal TGFaccess to food and water until the day of study.
response, defined as the difference between PSF values
recorded during perfusion of the loop with ATF at 0 andClearance and TGF measurements
40 nL · min21. Maximal rat TGF responses were deter-
Groups of SHRs and age-matched WKY rats were pre- mined in one to three nephrons.
pared for in vivo clearance, micropuncture, microperfu-
sion, and TGF studies as described in detail previously Series 1
[24]. In brief, animals were anesthetized with thiobarbital Measurements were made during perfusion of the LH
(Inactin, 100 mg · kg21 intraperitoneally; Research Bio- with ATF 1 vehicle and were contrasted with ATF 1
chemicals, Inc., Natick, MA, USA). A catheter was placed 7-NI (1024 mol/L). We had found previously that this
in a jugular vein for fluid infusion and in a femoral artery dose of 7-NI was maximally effective and produced a
for the recording of mean arterial pressure (MAP) from rapid and reversible increase in TGF responses [25].
the electrically damped output of a pressure transducer
Series 2(Statham, Gould Inc., Oxnard, CA, USA). A tracheot-
omy tube was inserted. The animals were allowed to In separate groups of rats, the EA supplying the test
breathe spontaneously. A catheter was placed in the nephron was perfused at 15 nL · min21 with artificial
bladder to collect urine from both kidneys. The left kid- plasma (AP) 1 tempol (1024 mol/L) [24] 2,2,6,6-tetra-
ney was exposed by a flank incision, cleaned of connec- methyl-1-piperidinyloxyl [2, 16, 17] and stained with
tive tissue, and stabilized in a Lucite cup. It was bathed FD&C green dye. After five minutes, with the EA mi-
in 0.154 mol/L NaCl maintained at 378C. After comple- croperfusion continuing, the TGF was tested with lumi-
tion of surgery, rats were infused with a solution of 0.154 nal perfusions of ATF 1 vehicle and ATF 1 7-NI at
0 and 40 nL · min21. The order of luminal perfusionsmol/L NaCl and 1% albumin at 1.5 mL · h21 to maintain a
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Table 1. Body weights, mean arterial pressure (MAP), heart rate (HR), urine flow (UV˙) and glomerular filtration rate (GFR)
Body wt MAP HR UV˙ GFR
Group N g mmHg beats ·min21 lL·min21 · 100 g21 mL·min21 · 100 g21
1. WKY, Veh 6 358617 12562 36865 1.760.3 0.7360.06
2. WKY, HHR 5 342612 9865 35568 1.860.3 0.7060.07
P values vs. #1 NS ,0.01 NS NS NS
3. WKY, Cand 6 358612 10362 36365 2.160.4 0.7960.08
P values vs. #1 NS ,0.01 NS NS NS
4. SHR, Veh 6 296610 16369 370611 2.060.4 0.5160.08
P values vs. #1 ,0.01 ,0.01 NS NS ,0.05
5. SHR, HHR 5 30769 11665 375612 1.760.3 0.5460.10
P values vs. #4 NS ,0.01 NS NS NS
6. SHR, Cand 6 285610 12165 36264 1.960.3 0.7960.09
P values vs. #4 NS ,0.01 NS NS ,0.05
Values are mean 6 SEM (N 5 number of rats studied) for rats of series 1. Abbreviations are in the Appendix.
was randomized. We have shown previously that EA not significantly different between the two treatments
perfusion with AP at 15 to 20 nL · min21 does not perturb or from the values of WKY rats given vehicle. Therefore,
the TGF responses [24]. Only nephrons in which the both treatments effectively normalized the MAP of the
surrounding interstitium was tinted with the colored AP SHR. These drugs also reduced the MAP of WKY rats.
perfusion solution were included in the study. The HRs and rates of urine flow were similar between
groups. The mean values for the GFR were significantly
Protocols (P , 0.05) lower by 31% in vehicle-treated SHRs com-
For 14 to 18 days, groups (N 5 6 to 8) of SHRs and pared with WKY rats. The GFR of SHRs was not modi-
WKY rats received a daily gavage with vehicle (Veh), fied by treatment with HHR but was increased signifi-
candesartan (Cand; 3 mg · kg21 · day21) or hydralazine 1 cantly (P , 0.05) by Cand to levels of vehicle-treated
hydrochlorothiazide 1 reserpine (HHR; 30 1 10 1 WKY rats.
0.2 mg · kg21 · day21). Drugs were withheld on the day Tubuloglomerular feedback parameters are shown in
of study. Table 2. The PSF at zero LH perfusion was elevated
(P , 0.05) by approximately 2 mm Hg in hypertensive
Drugs SHR given vehicle compared with equivalent WKY rats.
The soluble salt of 7-NI was obtained from Tocris Cook- This was anticipated from a prior study that had shown
son, Inc. (St. Louis, MO, USA). Tempol was obtained that the PSF at zero loop perfusion is dependent on
from Aldrich Chemical Co. (Milwaukee, WI, USA). the BP [26]. The maximal TGF responses during loop
Other chemicals were obtained from Sigma (St. Louis, perfusion with ATF 1 vehicle were enhanced signifi-
MO, USA). cantly (P , 0.001) by 35% in vehicle-administered SHR
compared with comparable WKY. Both Cand and HHRStatistical methods
reduced the exaggerated TGF responses of SHR signifi-
Values are reported as mean 6 SEM. A repeated- cantly (P , 0.001) to values comparable to the vehicle-
measures analysis of variance (ANOVA) was applied treated WKY, whereas these treatments did not modify
to data of SHRs and WKY rats administered vehicle, the TGF responses of the WKY.
candesartan, or HHR. Where appropriate, a post hoc The role of MD-derived NO in blunting TGF re-
Dunnett’s t test was applied thereafter. Values are taken sponses was assessed from the increase in TGF during
as statistically significant if P , 0.05. blockade of nNOS by luminal microperfusion of 7-NI
(Table 2). Whereas WKY had a consistent increase in
RESULTS maximal TGF responses with 7-NI of 2.8 6 0.4 mm Hg,
there was a significantly (P , 0.05) blunted rise of 1.1 6Data for whole kidney function in rats of series 1 are
0.6 mm Hg in vehicle-treated SHR. The increase in TGFshown in Table 1. Data for series 2 were strictly similar,
with 7-NI was not increased significantly above vehiclebut clearance measurements of glomerular filtration rate
treatment in WKY rats given HHR (2.8 6 0.6 mm Hg)(GFR) were made only in series 1. The body weights
or Cand (2.4 6 0.4 mm Hg). SHRs receiving HHR hadfor WKY rats at the time of study were significantly
only a modest increase in TGF with 7-NI of 1.8 6higher than SHR, reflecting their better rate of growth.
0.4 mm Hg that was not significantly different fromThe MAP was increased in the vehicle-administered
the increase in vehicle-administered SHRs of 1.1 6SHR compared with equivalent WKY. Both Cand and
HHR reduced the MAP of the SHRs to levels that were 0.6 mm Hg. However, SHRs receiving Cand had an in-
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Table 3. Proximal stop flow pressure (PSF) to luminal perfusion ofTable 2. Proximal stop flow pressure (PSF) during luminal
microperfusion of artificial tubular fluid (ATF) containing artificial tubular fluid (ATF) containing vehicle (Veh)
or 7-nitroindazole (7-NF) during microperfusion of tempolvehicle (Veh) or 7-nitroindazole (7-NI)
into the efferent arteriole
PSF (mm Hg) during LH microperfusion
at (nL·min21) PSF (mm Hg) during LH microperfusion
Added at (nL·min21)
AddedGroup to ATF 0 40 0–40
Group to ATF 0 40 0–40
WKY
WKY
1. WKY, Veh
1. WKY, Veh(N56) Veh 38.560.4 30.260.8 8.360.4
(N56) Veh 39.460.5 32.660.3 7.060.37-NI 38.260.4 27.160.6 11.260.4
7-NI 39.560.5 27.460.9 10.260.5D 10.160.3 22.960.9 12.860.4
D 10.160.3 25.360.9 13.260.5P value NS ,0.01 ,0.001
P value — 0.001 0.0012. WKY, HHR
2. WKY, HHR(N55) Veh 37.561.0 29.061.0 8.460.8
(N56) Veh 38.260.5 31.860.3 6.460.47-NI 38.061.1 26.660.7 11.260.8
7-NI 38.660.6 29.160.4 9.660.4D 10.460.4 22.460.8 12.860.6
D 10.560.3 22.660.5 13.260.5P value NS ,0.001 ,0.001
P value NS 0.001 0.0013. WKY, Cand
3. WKY, Cand(N56) Veh 36.860.5 28.760.5 7.860.3
(N58) Veh 38.960.4 32.160.3 6.960.57-NI 36.860.6 26.560.8 10.360.5
7-NI 38.760.3 29.260.4 9.660.4D 0.060.3 22.560.7 12.460.4
D 20.260.3 22.960.6 13.260.7P value NS ,0.001 ,0.001
P value NS 0.001 0.001
SHR
SHR
4. SHR, Veh
4. SHR, Veh(N56) Veh 40.060.8 29.260.5 10.960.7
(N57) Veh 41.160.4 33.460.5 7.560.57-NI 40.060.7 27.560.7 12.060.7
7-NI 40.960.5 27.060.6 13.860.4D 20.260.3 21.760.7 11.160.6
D 20.260.3 26.560.7 16.361.0P value NS ,0.05 NS
P value NS 0.001 0.0015. SHR, HHR
5. SHR, HHR(N55) Veh 37.260.7 29.760.6 7.360.7
(N57) Veh 39.760.7 32.960.5 6.960.57-NI 37.260.8 28.160.7 9.160.6
7-NI 39.261.1 27.860.5 11.561.0D 0.060.3 21.560.4 11.860.4
D 20.560.3 23.160.5 14.560.8P value NS ,0.001 ,0.01
P value NS 0.001 0.0016. SHR, Cand
6. SHR, Cand(N56) Veh 37.360.8 29.060.5 7.860.5
(N59) Veh 37.260.9 29.760.5 7.960.57-NI 37.260.8 26.060.4 11.460.7
7-NI 37.960.9 27.260.4 10.760.4D 10.160.3 23.060.7 13.460.5
D 10.760.5 22.660.5 12.960.9P value NS ,0.001 ,0.001
P value NS 0.001 0.001
Data are mean 6 SEM (N 5 number of rats studied). ATF is artificial tubular
fluid perfused orthograde through the loop of Henle. Data are mean 6 SEM values (N 5 number of rats studied). ATF is the
artificial tubular fluid perfused orthograde and through the loop of Henle.
crease in TGF with luminal 7-NI of 3.4 6 0.5 mm Hg
HHR, or Cand were not significantly different from thosethat was significantly (P , 0.05) greater than in SHRs
seen in the absence of tempol. In contrast, in vehicle-receiving HHR and significantly (P , 0.01) greater than
treated SHR microperfused with tempol, there was ain SHRs receiving vehicle. Cand effectively normalized
robust enhancement of TGF by 7-NI of 6.3 6 1.0 mm Hgthe TGF response to 7-NI; during candesartan, the re-
that was sixfold greater (P , 0.001) than the responsesponse of SHRs to 7-NI was not significantly different
to 7-NI of 1.1 6 0.6 mm Hg seen in the absence offrom vehicle-treated WKY rats. We conclude that SHRs
tempol. During the administration of HHR, SHR neph-have a diminished blunting of TGF by MD-derived NO
rons microperfused with tempol had an increase in TGFthat is restored in full by candesartan, but not by HHR.
with luminal 7-NI of 4.5 6 0.8 mm Hg that was threefoldTable 3 details the TGF responses to loop perfusion
greater (P , 0.01) than the increase of 1.8 6 0.4 mm Hgof ATF 1 7-NI compared with ATF 1 vehicle during
seen without tempol. This increase in TGF with 7-NIEA perfusion of tempol. As described previously, tempol
during tempol in SHRs treated with HHR was not sig-blunted TGF responses to ATF 1 vehicle more in SHR
nificantly different from SHRs treated with vehicle. Inthan WKY rat nephrons [5]. We interpret any effect of
contrast, during the administration of Cand, SHR neph-tempol to increase the effectiveness of 7-NI in enhancing
rons microperfused with tempol had an increase in TGFTGF to represent an effect of short-term abrogation of
with 7-NI of 2.9 6 0.9 mm Hg that was not significantlyoxidative stress to restore NO signaling in the JGA. As
different from the increase of 3.4 6 0.5 mm Hg seenshown in Figure 1, the increases in TGF produced by
luminal 7-NI in groups of WKY administered vehicle, without tempol. We conclude that the effects of O22 to
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Fig. 1. Mean 6 SEM values for absolute
increases in maximal tubuloglomerular feed-
back (TGF) responses during luminal perfu-
sion with artifical tubular fluid (ATF) 1 7-nitro-
indazole (7-NI; 1024 mol/L) compared with
ATF 1 vehicle. Data are compared in neph-
rons studied without (h; A or j; B) or during
( ) microperfusion of tempol (1024 mol/L)
in artificial plasma (AP) into the efferent arte-
riole (EA). Groups of WKY rats (A) or SHRs
(B) were administered with vehicle (Veh), hy-
dralazine 1 hydrochlorothiazide 1 reserpine
(HHR), or candesartan (Cand) for two weeks
prior to testing.
prevent blunting of TGF responses by NO were exagger- dependent on the extracellular fluid volume, it may be
that subtle differences in the experimental conditionsated in the SHRs. This effect was prevented in full only
by candesartan. between these studies underlie these divergent responses
to angiotensin blockade.
We showed previously that whereas microperfusion
DISCUSSION
of 7-NI into WKY rat nephrons to block nNOS increases
Brannstrom, Morsing, and Arendshorst reported that TGF significantly, it has little effect in SHR nephrons
a single intravenous bolus of candesartan normalizes the [25]. We postulated that this failure of a functional re-
exaggerated TGF responses of young SHR rat nephrons sponse to nNOS blockade in SHR nephrons might be a
[21]. This was confirmed in the present study, which secondary consequence of oxidative stress, since micro-
utilized adult SHRs that were administered candesartan perfusion of tempol into the JGA caused a very modest
over two weeks. In the prior study, candesartan normal- blunting of TGF of normotensive rats [15], but a signifi-
ized both the enhanced TGF-induced changes in PSF cantly enhanced blunting of the TGF in SHR [5]. The
and SNGFR, and the responsiveness and the set point present studies confirm that microperfusion of tempol
(sensitivity) of the TGF response. Our results extend the reduces the TGF of WKY modestly by 16%, yet reduces
prior evidence for an exaggerated role for AT1-R in the the TGF more prominently in SHR by 33% (Tables 2 and
kidneys of the SHR to the JGA [8–13]. In confirmation 3). A new finding in the present study is that prolonged
of the findings of Brannstrom et al with short-term cande- blockade of AT1 receptors in the SHR restores a normal
sartan [21], we found that this drug given over two weeks functional response to nNOS blockade (Fig. 1).
did not perturb the TGF response of normotensive WKY The administration of hydralazine, hydrochlorothia-
rats. Clearly, this was an effective dose of candesartan zide, and reserpine increases plasma renin activity in the
in WKY since it reduced the MAP in the current study rat [22]. These drugs were as effective as candesartan in
(Table 1), and the dose used by Brannstrom et al blocked reducing the BP and normalizing the TGF responses in
the renal and systemic effects of infused Ang II [21]. the SHR. Nevertheless, there were important differences
These results differ from the short-term effects of an in the responses of the SHR kidney to the two types
angiotensin-converting enzyme inhibitor [27–29] or an of therapy. First, only AT1-R blockade normalized the
Ang II antagonist [29, 30], which impairs TGF responses reduced GFR. Second, only AT1-R blockade normalized
in normotensive rats. Moreover, mice with targeted dis- the TGF responses to nNOS blockade with 7-NI. We
ruption of the AT1 receptor have no TGF responses [31]. conclude that prolonged AT1-R blockade has specific
In the present study, candesartan failed to blunt the TGF effects in the JGA of the SHR model of hypertension
responses despite a fall in MAP, which itself normally de- above those of reducing the BP.
Mitchell et al have shown that tempol acts as an SODpresses TGF [26]. Since the effects of Ang II are strictly
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mimetic and enhances H2O2 metabolism to O2 and H2O responses. This points to an important role for hyperten-
sion per se in the exaggerated TGF responses of the[16, 32, 33]. It is highly permeable to cell membranes
and is not toxic. It does not bind directly to nor generate SHR [26]. However, Cand restored in full a normal TGF
response to the blockade of nNOS, whereas HHR wasNO [33]. It is a validated spin-trap for O22 in electron
paramagnetic resonance studies [32]. Tempol protects not effective. Of particular interest were differences in
the effects of tempol on the responses to 7-NI. SHRcells and tissues against oxidative stress [34]. It reduces
the elevated BP, the excretion of 8-iso-PGF2a, and the treated with HHR had an enhanced TGF responses to
7-NI during local microperfusion of tempol that wasrenal vascular resistance of the SHR [2, 4]. Microperfu-
sion of tempol into the EA enhances the sensitivity and quite similar to SHR treated with vehicle. This suggests
that HHR did little to abrogate oxidative stress, despiteresponsiveness of NO donor compounds in blunting
TGF when applied to the lumen of the MD [5]. There- its effects in lowering BP (Fig. 1), possibly because any
beneficial effects of a two-week reduction in BP pro-fore, tempol was selected for these studies to evaluate
the role of excessive O22 generation in the SHR. duced by HHR were offset by an enhanced release of
renin and activation of AT1 receptors [22]. In contrast,Macula densa-derived NO establishes the set point for
TGF during long-term adaptation to changes in proximal SHR treated with candesartan had a TGF response to
7-NI that was unaffected by tempol. This is consistentreabsorption [35]. Prolonged inhibition of nNOS with
oral 7-NI in normal rats first enhances TGF and later with the hypothesis that AT1-R blockade had effectively
prevented the oxidative stress that is characteristic ofinduced hypertension [36]. These studies establish an
important long-term role for MD nNOS to modulate the SHR. Thus, oxidative stress in the JGA of the SHR
can be ascribed to prolonged stimulation of AT1-R.TGF. However, an intact nNOS is not an absolute re-
quirement for TGF responses since TGF is normal in Blockade of AT1-R apparently restores normal oxidative
function and NO signaling within the JGA, restores anNOS knockout mice (abstract; Schnermann et al, J Am
Soc Nephrol 10:387A, 1999). The exaggerated blunting normal level of glomerular filtration, and reverses hyper-
tension. Further studies are required to test whether theof TGF by tempol in SHR confirms a prior study [5].
There is a diminished buffering of TGF by NO derived special effect of angiotensin-converting enzyme inhibi-
from nNOS in the JGA of the SHR since, as in previous tion in preventing progressive renal damage in hyperten-
studies [25, 37], there was no significant response of TGF sion [22] also depends on restoring a normal functional
to blockade of NOS in SHR nephrons. The present study role for NO.
provides evidence that this diminished role for NO in
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nitrite (ONOO2), which is formed by the reaction of
APPENDIXNO and O22 , can nitrate tyrosine residues in proteins.
Bosse and Bachmann showed intense nitrotyrosine im- Abbreviations used in this article are: Ang II, angiotensin II; AP,
artificial plasma; AT1, angiotensin II type 1; AT1-R, angiotensin IImunoreactivity in the Ang II-stimulated postclip kidney
type 1 receptor; ATF, artificial tubular fluid; Cand, candesartan; EA,of Goldblatt hypertensive rats [20]. Immunoreactivity
efferent arteriole; GFR, glomerular filtration rate; HHR, hydralazine 1
was expressed strongly in the interstitial spaces between hydrochlorothiazide 1 reserpine; HR, heart rate; JGA, juxtaglomeru-
lar apparatus; LH, loop of Henle; MAP, mean arterial pressure; MD,the MD and the afferent arteriole. This suggests that
macula densa; 7-NI, 7-nitroindazole; NO, nitric oxide, nNOS, neuronalO22 , likely generated from nicotinamide adenine dinucle- nitric oxide synthase; O22 , oxygen radical; PSF, proximal stop flowotide phosphate (NADPH) oxidase that is expressed pressure; SHR, spontaneously hypertensive rat; SOD, superoxide dis-
mutase; TGF, tubuloglomerular feedback; Veh, vehicle; WKY, Wistarin interstitial fibroblasts and mesangial cells [19] and is
Kyoto rat.stimulated by Ang II [18], forms a barrier in the hyper-
tensive kidney that limits the effects of MD derived NO
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